These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32585160)

  • 1. Advances in functional and molecular MRI technologies in chronic liver diseases.
    Zhou IY; Catalano OA; Caravan P
    J Hepatol; 2020 Nov; 73(5):1241-1254. PubMed ID: 32585160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism.
    Choi Y; Huh J; Woo DC; Kim KW
    Br J Radiol; 2016; 89(1058):20150666. PubMed ID: 26693795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abdominal MR: liver and pancreas.
    Bartolozzi C; Lencioni R; Donati F; Cioni D
    Eur Radiol; 1999; 9(8):1496-512. PubMed ID: 10525857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liver-specific MR contrast agents: current status and prospects].
    Tanimoto A
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Sep; 61(10):525-33. PubMed ID: 11676169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation of liver cells in health and disease.
    Kmieć Z
    Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic MRI with SPIO: detection and characterization of focal liver lesions.
    Reimer P; Tombach B
    Eur Radiol; 1998; 8(7):1198-204. PubMed ID: 9724439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
    Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
    Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison between dynamic gadoxetate-enhanced MRI and
    Rassam F; Zhang T; Cieslak KP; Lavini C; Stoker J; Bennink RJ; van Gulik TM; van Vliet LJ; Runge JH; Vos FM
    Eur Radiol; 2019 Sep; 29(9):5063-5072. PubMed ID: 30796575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast agents for hepatic MRI.
    Morana G; Salviato E; Guarise A
    Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S24-7. PubMed ID: 17921081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Organ specific MRI contrast media in general practice].
    Schima W
    Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury.
    Getzin T; Gueler F; Hartleben B; Gutberlet M; Thorenz A; Chen R; Meier M; Bräsen JH; Derlin T; Hartung D; Lang HAS; Haller H; Wacker F; Rong S; Hueper K
    Eur Radiol; 2018 Oct; 28(10):4455-4464. PubMed ID: 29713782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes.
    Ketkar-Atre A; Struys T; Dresselaers T; Hodenius M; Mannaerts I; Ni Y; Lambrichts I; Van Grunsven LA; De Cuyper M; Himmelreich U
    Biomaterials; 2014 Jan; 35(3):1015-24. PubMed ID: 24210051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?
    Savic LJ; Doemel LA; Schobert IT; Montgomery RR; Joshi N; Walsh JJ; Santana J; Pekurovsky V; Zhang X; Lin M; Adam L; Boustani A; Duncan J; Leng L; Bucala RJ; Goldberg SN; Hyder F; Coman D; Chapiro J
    Radiology; 2020 Sep; 296(3):575-583. PubMed ID: 32633675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.
    Ayyala RS; Anupindi SA; Gee MS; Trout AT; Callahan MJ
    Pediatr Radiol; 2019 Sep; 49(10):1256-1268. PubMed ID: 31350632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New imaging techniques for liver diseases.
    Van Beers BE; Daire JL; Garteiser P
    J Hepatol; 2015 Mar; 62(3):690-700. PubMed ID: 25457198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis: Review of current imaging and MRI quantification techniques.
    Petitclerc L; Sebastiani G; Gilbert G; Cloutier G; Tang A
    J Magn Reson Imaging; 2017 May; 45(5):1276-1295. PubMed ID: 27981751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments.
    Ni Y; Marchal G
    Top Magn Reson Imaging; 1998 Jun; 9(3):183-95. PubMed ID: 9621406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.
    Verloh N; Haimerl M; Zeman F; Schlabeck M; Barreiros A; Loss M; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
    Eur Radiol; 2014 May; 24(5):1013-9. PubMed ID: 24531844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.